Publication: Progress in Retinal and Eye Research
Explore the groundbreaking evolution of retinal therapeutics since the approval of the first anti-VEGF therapy in 2004. This article, authored by Partner Dmitrij Hristodorov, Senior Associate Tim Lohoff, General Partner Nanna Luneborg, Managing Partner Geert-Jan Mulder, and Advisor Simon J Clark, delves into the remarkable transformation of the field, witnessing a surge in novel, disease-modifying treatments addressing a diverse range of retinal diseases. Venture capital investors, recognizing the scientific advancements and urgent medical needs, have collectively invested close to $10 billion in research and development between 2004 and 2023. The narrative unfolds with a shift in focus from competing with anti-VEGF therapeutics in exudative diseases to reducing the overall treatment burden. Simultaneously, a new era emerges in non-exudative fields, leading to promising drug candidates and significant approvals, such as Luxturna for Retinitis pigmentosa. The article provides a comprehensive review of the past two decades, covering achievements, challenges, and contextualizing investments, partnerships, and acquisitions. It concludes with an optimistic outlook and potential roadmap for novel retinal therapeutics, emphasizing the potential to stimulate further venture capital investments for the development and delivery of new therapies to patients in need.
Click here to access the article online.